Evotec looks to China for first development deal for anti-inflammatory candidate
This article was originally published in Scrip
Evotec of Germany has granted the Chinese company Conba Pharmaceutical development and marketing rights in China to EVT 401, a selective, small molecule P2X7 antagonist, for human indications with the exception of ophthalmological disorders, chronic obstructive pulmonary disease (COPD) and endometriosis.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.